ENDOMETRIAL NEOPLASMS
Clinical trials for ENDOMETRIAL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL NEOPLASMS trials appear
Sign up with your email to follow new studies for ENDOMETRIAL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a common cancer drug help rare tumors? new trial aims to find out
Disease control Recruiting nowThis trial tests atezolizumab, a drug already approved for several cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 wee…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New drug DM002 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New hope for rare gynecological cancer: immunotherapy combo tested against chemo
Disease control Recruiting nowThis study tests whether the immunotherapy drug dostarlimab, alone or combined with bevacizumab, works better than standard chemotherapy for people with recurrent gynecological clear cell carcinoma. About 198 participants will be randomly assigned to one of three treatment groups…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug, NKT3964, designed to break down a protein called CDK2 that helps cancer cells grow. The trial includes adults with advanced or metastatic solid tumors, such as ovarian, endometrial, breast, gastric, and lung cancers, whose disease has…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New hope for recurrent endometrial cancer: drug combo shows promise
Disease control Recruiting nowThis study is for people with endometrial cancer that has come back or spread to a few other spots. It tests a new drug called cadonilimab given together with standard chemotherapy and radiation. The goal is to see if this combination can shrink tumors and help people live longer…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
Controversial tool under scrutiny: could a simple device raise cancer recurrence risk?
Knowledge-focused Recruiting nowThis trial is testing whether using a uterine manipulator during minimally invasive hysterectomy for endometrial cancer affects the chance of cancer coming back. About 1,030 women with early-stage endometrial cancer will be randomly assigned to have surgery with or without the de…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: NA • Sponsor: Universita di Verona • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:56 UTC
-
New cancer registry tracks Real-Life treatment outcomes
Knowledge-focused Recruiting nowThis study is a German registry that will follow about 2,000 people with advanced ovarian or endometrial cancer. Researchers will collect information on the treatments patients actually receive, how well they work, and how patients feel. The goal is to understand real-world care …
Matched conditions: ENDOMETRIAL NEOPLASMS
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:01 UTC